225 related articles for article (PubMed ID: 10769689)
1. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
4. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
6. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.
Pang S; Dannull J; Kaboo R; Xie Y; Tso CL; Michel K; deKernion JB; Belldegrun AS
Cancer Res; 1997 Feb; 57(3):495-9. PubMed ID: 9012480
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
8. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
11. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
[TBL] [Abstract][Full Text] [Related]
12. [Constructing recombinant plasmid with prostate-specific membrane antigen promoter and reverse enhancer and comparing the transcription activity of enhancers in different directions].
Zeng H; Liao YC; Wang F; Wu Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Nov; 36(6):782-5. PubMed ID: 16334552
[TBL] [Abstract][Full Text] [Related]
13. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Trofimova I; Dimtchev A; Jung M; Rosenthal D; Smulson M; Dritschilo A; Soldatenkov V
Cancer Res; 2002 Dec; 62(23):6879-83. PubMed ID: 12460902
[TBL] [Abstract][Full Text] [Related]
15. Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.
Chapel-Fernandes S; Jordier F; Lauro F; Maitland N; Chiaroni J; de Micco P; Mannoni P; Bagnis C
Cancer Gene Ther; 2006 Oct; 13(10):919-29. PubMed ID: 16741521
[TBL] [Abstract][Full Text] [Related]
16. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
17. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
Majumdar S; Diamandis EP
Br J Cancer; 1999 Mar; 79(9-10):1594-602. PubMed ID: 10188912
[TBL] [Abstract][Full Text] [Related]
18. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action.
Bigler D; Gulding KM; Dann R; Sheabar FZ; Conaway MR; Theodorescu D
Oncogene; 2003 Feb; 22(8):1261-72. PubMed ID: 12606954
[TBL] [Abstract][Full Text] [Related]
19. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
